Answer
The licence includes men receiving adjuvant treatment for eligible early breast cancer with an aromatase inhibitor and an LHRH agonist. The selected product’s advanced-disease indication is worded for women.
Sources for this answer
- Kisqali film coated tablets — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.